{"id":"solifenacin-succinate-suspension","safety":{"commonSideEffects":[{"rate":"11-27%","effect":"Dry mouth"},{"rate":"13-15%","effect":"Constipation"},{"rate":"5-8%","effect":"Blurred vision"},{"rate":"1-2%","effect":"Urinary retention"},{"rate":"4-6%","effect":"Headache"},{"rate":"2-3%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, preventing involuntary contractions. This reduces urinary frequency, urgency, and incontinence episodes associated with overactive bladder syndrome. The suspension formulation allows for flexible dosing and is particularly useful in patients who have difficulty swallowing tablets.","oneSentence":"Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:45.885Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT01565694","phase":"PHASE3","title":"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-08-14","conditions":"Neurogenic Detrusor Overactivity","enrollment":76},{"nctId":"NCT01655069","phase":"PHASE3","title":"A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-10-04","conditions":"Urinary Bladder, Overactive","enrollment":148},{"nctId":"NCT01565707","phase":"PHASE3","title":"A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-06-07","conditions":"Urinary Bladder, Overactive","enrollment":189},{"nctId":"NCT01981954","phase":"PHASE3","title":"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-09-25","conditions":"Neurogenic Detrusor Overactivity, Pediatric","enrollment":23},{"nctId":"NCT01262391","phase":"PHASE1","title":"Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2010-10-20","conditions":"Urinary Bladder, Overactive","enrollment":42},{"nctId":"NCT01539707","phase":"PHASE1","title":"Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2012-03-13","conditions":"Overactive Bladder, Neurogenic Detrusor Overactivity","enrollment":14},{"nctId":"NCT01406158","phase":"PHASE1","title":"A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-05","conditions":"Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers","enrollment":24},{"nctId":"NCT01015040","phase":"PHASE1","title":"Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-09","conditions":"Bioavailability of Solifenacin Succinate, Pharmacokinetics of Solifenacin Succinate, Healthy Volunteers","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YM905","VESIcare","solifenacin succinate"],"phase":"marketed","status":"active","brandName":"solifenacin succinate suspension","genericName":"solifenacin succinate suspension","companyName":"Astellas Pharma Inc","companyId":"astellas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}